Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study-Reference-Cited by-同舟云学术

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:410-411
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Houot Roch¹,Bachy Emmanuel²,Cartron Guillaume³,Gros François-Xavier⁴,Morschhauser Franck⁵,Oberic Lucie⁶,Gastinne Thomas⁷,Feugier Pierre⁸,Dulery Remy⁹,Thieblemont Catherine¹⁰,Joris Magalie¹¹,Llamas-Gutierrez Francisco¹²,Itti Emmanuel¹³,Menard Cedric¹⁴,Al-Tabaa Yassine¹⁵,Bailly Clement¹⁶,Delfau Marie-Helene¹⁷,Laurent Camille¹⁸,Lemonnier Francois¹⁹

Affiliation:

1. 1CHU de Rennes, Université de Rennes, INSERM U1236, EFS, Rennes, France

2. 2Department of Hematology, Lyon-Sud Hospital, Pierre-Benite, France

3. 3Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France

4. 4Hopital Du Haut-lévèQue, Pessac, FRA

5. 5Hematology Department, Lille University Hospital, Lille, France

6. 6Department of Hematology, Institut Universitaire Cancerologie Toulouse-Oncopole, Toulouse, France

7. 7Hematology Department, Nantes University Hospital, Nantes, France

8. 8Department of Hematology, Henri Poincaré University, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France

9. 9Saint-Antoine Research Center, Inserm UMR938, Sorbonne Université, Paris, France

10. 10Hôpital Saint-Louis, Paris, France

11. 11Service d'Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d'Amiens, Amiens, France

12. 12Hemopathology lab, University hospital of Rennes, Rennes, France

13. 13Nuclear Medicine, Henri Mondor Hospital, Créteil, France

14. 14SITI laboratory, University Hospital Pontchaillou, Rennes, France

15. 15Scintidoc Nuclear Medicine Center, Montpellier, France

16. 16Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France

17. 17Department of Immunology, University Hospital, Creteil, France

18. 18Institut universitaire du cancer Toulouse-Oncopole CHU Toulouse, Toulouse, France

19. 19Unité Hémopathie Lymphoïde, Hôpital Henri Mondor & Université Paris Est Créteil, Créteil, France

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas;Expert Opinion on Biological Therapy;2024-02-02

2. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature;The Lancet Infectious Diseases;2024-02

3. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning;Expert Opinion on Biological Therapy;2023-12-02

4. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma;Transplantation and Cellular Therapy;2023-09

5. Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach;European Journal of Haematology;2023-08-29